红葡萄酒和摩卡咖啡在轻度血管认知障碍中的联合作用
Manuela Pennisi1, Mariagiovanna Cantone2, Francesco Cappellani3
1Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Experimental gerontology
|June 20, 2024
概括
适度饮用咖啡和红酒可能会在患有轻度血管认知障碍 (VCI) 的患者中协同有益于情绪和认知. 然而,大量摄入任何一种药物,对认知表现产生不利影响.
科学领域:
- 神经科学是一个神经科学.
- 营养精神病学 营养精神病学
背景情况:
- 适度咖啡摄入量与轻度血管认知障碍 (VCI) 患者的情绪和认知能力的改善有关.
- 红葡萄酒消费已证明对阿尔茨海默病和血管痴呆症等认知障碍有保护作用.
研究的目的:
- 研究红葡萄酒和咖啡消费在轻度VCI患者的心情和认知状态之间的协同关系.
- 评估不同水平的咖啡和红酒摄入量对认知功能和情绪的影响.
主要方法:
- 300名患有轻度VCI的非痴呆老年患者接受了关于咖啡和红酒消费的调查.
- 参与者完成了情绪 (汉密尔顿抑郁评分表),认知 (迷你精神状态检查,Stroop颜色-词干扰测试) 和功能独立 (日常生活活动) 的评估.
- 线性回归模型分析了饮食摄入量与健康结果之间的关联.
主要成果:
- 在所有咖啡消费水平上,适度的葡萄酒摄入与更好的执行功能相关 (Stroop T分数).
- 大量的葡萄酒消费,特别是高咖啡摄入量,与较差的执行功能有关.
- 综合适量咖啡和红葡萄酒摄入量导致抑郁症得分最低 (HDRS) 和最佳认知表现 (MMSE).
结论:
- 在轻度VCI患者中,每天适量摄入咖啡和红葡萄酒似乎对全球认知,执行功能和情绪有协同的保护作用.
- 观察到的好处是非线性的,适度的消费是保护性的,大量的消费是有害的.
- 需要进一步的研究来证实这些发现,并探索长期影响.
相关概念视频
01:27CNS Depressants: Alcohol and Nicotine
202
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
202
01:27Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
01:30Combined Effects of Drugs: Antagonism
8.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.4K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462